PMID- 27742235
OWN - NLM
STAT- MEDLINE
DCOM- 20170711
LR  - 20220316
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 27
IP  - 11
DP  - 2016 Nov
TI  - Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia.
PG  - 1686-1697.e8
LID - S1051-0443(16)30439-0 [pii]
LID - 10.1016/j.jvir.2016.08.004 [doi]
AB  - PURPOSE: To perform meta-analysis of available data on prostatic artery 
      embolization (PAE). MATERIALS AND METHODS: Meta-analysis was conducted on 
      articles published between November 2009 and December 2015. Peer-reviewed studies 
      with > 5 patients and standard deviations and/or individual-level data on one or 
      more of the following outcomes were included: prostate volume (PV), peak flow 
      rate (Qmax), postvoid residual (PVR), International Prostate Symptom Score 
      (IPSS), quality of life (QOL) score, International Index of Erectile Function 
      (IIEF) score, and prostate-specific antigen (PSA) level. A random-effects 
      meta-analysis was performed on the outcomes at 1, 3, 6, and 12 months after PAE 
      compared with baseline values, with a P < .05 decision rule as the null 
      hypothesis rejection criterion. RESULTS: Nineteen of 268 studies were included in 
      data collection, with 6 included in the meta-analysis. At 12 months, PV decreased 
      by 31.31 cm(3) (P < .001), PSA remained unchanged (P = .248), PVR decreased by 
      85.54 mL (P < .001), Qmax increased by 5.39 mL/s (P < .001), IPSS improved by 
      20.39 points (P < .001), QOL score improved by -2.49 points (P < .001), and IIEF 
      was unchanged (P = 1.0). There were a total of 218 adverse events (AEs) among 662 
      patients (32.93%), with 216 being Society of Interventional Radiology class A/B 
      (99%). The most common complications were rectalgia/dysuria (n = 60; 9.0%) and 
      acute urinary retention (n = 52; 7.8%). No class D/E complications were reported. 
      CONCLUSIONS: PAE provided improvement in Qmax, PVR, IPSS, and QOL endpoints at 12 
      months, with a low incidence of serious AEs (0.3%), although minor AEs were 
      common (32.93%). There was no adverse effect on erectile function.
CI  - Copyright (c) 2016 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Uflacker, Andre
AU  - Uflacker A
AD  - Department of Radiology and Medical Imaging, Division of Vascular and 
      Interventional Radiology, University of Virginia, 1215 Lee St., Charlottesville, 
      VA 22908.
FAU - Haskal, Ziv J
AU  - Haskal ZJ
AD  - Department of Radiology and Medical Imaging, Division of Vascular and 
      Interventional Radiology, University of Virginia, 1215 Lee St., Charlottesville, 
      VA 22908. Electronic address: haskaljvir@gmail.com.
FAU - Bilhim, Tiago
AU  - Bilhim T
AD  - Interventional Radiology Department, Saint Louis Hospital, Lisbon, Portugal.
FAU - Patrie, James
AU  - Patrie J
AD  - Department of Public Health Sciences, University of Virginia, 1215 Lee St., 
      Charlottesville, VA 22908.
FAU - Huber, Timothy
AU  - Huber T
AD  - Department of Radiology and Medical Imaging, Division of Vascular and 
      Interventional Radiology, University of Virginia, 1215 Lee St., Charlottesville, 
      VA 22908.
FAU - Pisco, Joao Martins
AU  - Pisco JM
AD  - Interventional Radiology Department, Saint Louis Hospital, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Webcast
DEP - 20161012
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - EC 3.4.21.- (KLK3 protein, human)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - J Vasc Interv Radiol. 2017 May;28(5):772. PMID: 28431657
CIN - J Vasc Interv Radiol. 2017 May;28(5):772-773. PMID: 28431658
MH  - *Arteries/diagnostic imaging
MH  - Embolization, Therapeutic/adverse effects/*methods
MH  - Humans
MH  - Kallikreins/blood
MH  - Male
MH  - Prostate/*blood supply
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Hyperplasia/diagnostic imaging/*therapy
MH  - Quality of Life
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2016/10/16 06:00
MHDA- 2017/07/14 06:00
CRDT- 2016/10/16 06:00
PHST- 2016/05/07 00:00 [received]
PHST- 2016/08/02 00:00 [revised]
PHST- 2016/08/05 00:00 [accepted]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2016/10/16 06:00 [entrez]
AID - S1051-0443(16)30439-0 [pii]
AID - 10.1016/j.jvir.2016.08.004 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2016 Nov;27(11):1686-1697.e8. doi: 
      10.1016/j.jvir.2016.08.004. Epub 2016 Oct 12.